46,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Breast cancer is a complex disease with many factors that can contribute to its development. As such, informative biomarkers are required to accurately and comprehensively characterize breast cancer so that patient management is both informed and optimal. Current breast cancer biomarkers, although useful, have limitations and are sometimes unable to classify all breast cancer patients. Therefore, new classes of biomarkers and detection tools are needed. A possible complement to existing biomarkers is the aberrant DNA methylation of miRNA promoters in breast cancer. This book will take the…mehr

Produktbeschreibung
Breast cancer is a complex disease with many factors that can contribute to its development. As such, informative biomarkers are required to accurately and comprehensively characterize breast cancer so that patient management is both informed and optimal. Current breast cancer biomarkers, although useful, have limitations and are sometimes unable to classify all breast cancer patients. Therefore, new classes of biomarkers and detection tools are needed. A possible complement to existing biomarkers is the aberrant DNA methylation of miRNA promoters in breast cancer. This book will take the reader on a journey from discovering a novel biomarker to developing a new technology for detecting this potential biomarker in clinical practice. The genetics/biotechnology interdisciplinary combination may appeal to readers majoring in either field and to anyone interested in interdisciplinary research.
Autorenporträt
Eugene J.H. Wee, PhD in cancer genetics from The University of Queensland, Australia. Postdoctoral researcher at the Australian Institute for Bioengineering and Nanotechnology.